Dechra announced earlier today that it has received approval from the FDA for its pergolide tablets (Zygolide; Dechra) to ...

Zygolide ® is a first-to-market generic, peppermint-flavored pergolide tablet, offering enhanced features for horses ...

Corcept Therapeutics (CORT) leverages Korlym’s commercial success in hypercortisolism, generating $559.3M in nine-month 2025 ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism ...

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...

Corcept shares crash as the FDA rejects its application for relacorilant. But is it worth buying CORT stock on the pullback?

The FDA has issued a complete response letter for an oral selective glucocorticoid receptor antagonist under investigation ...

Amy Schumer has lost a considerable amount of weight over the past few months—over 50 pounds to date—and says that her weight loss journey was brought on by her Cushing Syndrome diagnosis, saying she ...

Corcept stock tanks as FDA setback hits relacorilant for Cushing’s syndrome. Truist analysts believe CORT shares pullback may ...

The U.S. FDA dashed hopes that Corcept Therapeutics Inc. might be able to launch its selective glucocorticoid receptor ...

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with ...